Gestational Diabetes

Current Guidance Update

WHO 2013 Criteria (Reaffirmed 2024)

GDM Diagnosis

Gestational diabetes is diagnosed by a 75g OGTT with values of fasting ≥5.1 mmol/L, 1-hour ≥10.0 mmol/L, or 2-hour ≥8.5 mmol/L.

NICE NG3 (Updated 2023)

Blood Glucose Targets

Self-monitoring of blood glucose is recommended with target fasting levels under 5.3 mmol/L and 1-hour post-meal levels under 7.8 mmol/L.

ACOG Practice Bulletin #190 (2024)

Medical Management

Metformin and glyburide may be appropriate alternatives for some women, although insulin remains the first-line treatment.

FIGO GDM Initiative (2023)

Universal Screening

Universal screening with a 75g Oral Glucose Tolerance Test (OGTT) between 24–28 weeks is recommended for all pregnancies worldwide.

Introduction

Gestational diabetes mellitus (GDM) is defined as glucose intolerance first recognised during pregnancy and represents one of the most common medical complications of pregnancy worldwide. In the UAE and broader Gulf region, GDM prevalence is among the highest globally — estimated at 15–25% of pregnancies — driven by elevated background prevalence of type 2 diabetes risk factors in the regional population. GDM is clinically important both for the immediate pregnancy and as a marker for substantially elevated long-term maternal diabetes risk.

Gestational Diabetes Overview

Risk Factors

BMI ≥25 kg/m² with progressively increasing risk at higher BMI.

Previous gestational diabetes or previous macrosomic infant.

First-degree family history of type 2 diabetes.

South Asian, Middle Eastern, African or Hispanic ethnicity.

Polycystic Ovary Syndrome (PCOS).

Maternal age of 35 years and above.

Multiple pregnancy.

Combination of multiple metabolic risk factors.

Diagnosis

Gestational diabetes is diagnosed using a 75g Oral Glucose Tolerance Test (OGTT) after an overnight fast. Diagnosis is confirmed when any single value meets or exceeds the WHO 2013 threshold. Women at high risk should be screened at booking and again between 24–28 weeks if the initial test is normal.

Fetal & Neonatal Risks

Macrosomia leading to difficult delivery and shoulder dystocia.

Neonatal hypoglycaemia.

Preterm birth and respiratory distress syndrome.

Long-term obesity and increased type 2 diabetes risk in the child.

Maternal Risks

Preeclampsia with a 2–4 times higher risk.

Increased caesarean section rate.

Approximately 50% develop type 2 diabetes within 10 years.

GDM recurrence risk of 50–70% in future pregnancies.

Gestational Diabetes Management

Management

Approximately 70–80% of women achieve adequate glucose control through dietary and lifestyle modification, including consistent carbohydrate distribution, low-GI food choices, regular physical activity, and appropriate pregnancy weight gain.

Self-monitoring of blood glucose remains standard practice, with recommended targets of fasting below 5.3 mmol/L and 1-hour post-meal below 7.8 mmol/L.

When lifestyle measures are insufficient, insulin remains the gold standard treatment, while metformin and glyburide may be considered appropriate alternatives in selected centres.

Postpartum Care

Glucose Testing

Fasting glucose or HbA1c assessment is recommended between 6–13 weeks postpartum.

Annual Screening

Women should continue annual diabetes screening for life following gestational diabetes.

Healthy Lifestyle

Maintain dietary improvements and regular physical activity to reduce the future risk of type 2 diabetes.

Breastfeeding

Breastfeeding is strongly encouraged and is associated with a reduced long-term risk of type 2 diabetes.

Frequently Asked Questions

Will I definitely develop type 2 diabetes after GDM?

Not definitely, but risk is significantly elevated — approximately 50% within 10 years without intervention. Lifestyle modification substantially reduces this risk.

Is GDM my fault?

No. GDM results from genetic predisposition, ethnicity, pregnancy hormones, and metabolic factors combined — not individual behaviour.

Can I eat normally if I have GDM?

Dietary modification rather than strict restriction allows most women to achieve good glucose control while maintaining adequate nutrition.

Conclusion

Gestational diabetes is common, clinically significant, and highly manageable with the right support. In Dubai's high-risk population, structured screening and individualised management are essential to optimising outcomes.

Sources & References

This article draws on guidance current at the time of writing from the following bodies and publications:

WHO 2013 Criteria (reaffirmed 2024)
NICE NG3 (updated 2023)
ACOG Practice Bulletin #190 (2024)
FIGO (2023 GDM Initiative)

General reference bodies for women's health guidance:

RCOG

rcog.org.uk

ACOG

acog.org

FIGO

figo.org

WHO

who.int

NICE

nice.org.uk

⚠ IMPORTANT DISCLAIMER

This article is provided for general knowledge and reference purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition.

Consult Dr. Ruby Rashmi

Specialist Obstetrician & Gynecologist, Dubai